Literature DB >> 11483919

Heparin-induced thrombocytopenia is rare in pregnancy.

M B Fausett1, M Vogtlander, R M Lee, M S Esplin, D W Branch, G M Rodgers, R M Silver.   

Abstract

OBJECTIVE: The indications for heparin use during pregnancy are expanding; however, heparin is associated with serious adverse effects including heparin-induced thrombocytopenia. Low-molecular-weight heparin is expensive but is associated with less frequent occurrences of heparin-induced thrombocytopenia in the nonpregnant population. However, the incidence of heparin-induced thrombocytopenia during pregnancy is unknown. The purpose of this study was to compare the incidence of heparin-induced thrombocytopenia in pregnant and nonpregnant women. STUDY
DESIGN: This is a retrospective cohort comparison. Pregnant and nonpregnant women were identified by means of diagnosis related group and Current Procedural Terminology code searches at three medical centers in Utah; the incidence of heparin-induced thrombocytopenia in the two groups was compared.
RESULTS: There were 10 (4%) cases of thrombocytopenia among 244 heparin-treated pregnant patients and 26 (11%) cases among the 244 nonpregnant controls. There were no cases of heparin-induced thrombocytopenia in the pregnant group, but there were 10 (4%) cases in the control group (P =.0014).
CONCLUSION: Heparin-induced thrombocytopenia is extremely rare in pregnant women.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11483919     DOI: 10.1067/mob.2001.114690

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  9 in total

Review 1.  Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Lori-Ann Linkins; Antonio L Dans; Lisa K Moores; Robert Bona; Bruce L Davidson; Sam Schulman; Mark Crowther
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

2.  Natural language processor as a tool to assess heparin induced thrombocytopenia awareness.

Authors:  Alfonso J Tafur; Robert D McBane; Waldemar E Wysokinski; Melissa S Gregg; Paul R Daniels; David N Mohr
Journal:  J Thromb Thrombolysis       Date:  2012-01       Impact factor: 2.300

Review 3.  Heparin-induced thrombocytopenia.

Authors:  Gowthami M Arepally
Journal:  Blood       Date:  2017-04-17       Impact factor: 22.113

Review 4.  Immune pathogenesis of heparin-induced thrombocytopenia.

Authors:  Sanjay Khandelwal; Gowthami M Arepally
Journal:  Thromb Haemost       Date:  2016-07-28       Impact factor: 5.249

5.  Determinants of PF4/heparin immunogenicity.

Authors:  Shayela Suvarna; Benjamin Espinasse; Rui Qi; Rauova Lubica; Mortimer Poncz; Douglas B Cines; Mark R Wiesner; Gowthami M Arepally
Journal:  Blood       Date:  2007-09-11       Impact factor: 22.113

Review 6.  Heparin Induced Thrombocytopenia for the Perioperative and Critical Care Clinician.

Authors:  Ingrid Moreno-Duarte; Kamrouz Ghadimi
Journal:  Curr Anesthesiol Rep       Date:  2020-08-29

Review 7.  Pulmonary Embolism and Pregnancy-Challenges in Diagnostic and Therapeutic Decisions in High-Risk Patients.

Authors:  Lukas Hobohm; Ioannis T Farmakis; Thomas Münzel; Stavros Konstantinides; Karsten Keller
Journal:  Front Cardiovasc Med       Date:  2022-03-08

Review 8.  Management of Anticoagulation in Pregnant Women With Mechanical Heart Valves.

Authors:  Molly M Daughety; Jevgenia Zilberman-Rudenko; Joseph J Shatzel; Owen J T McCarty; Vikram Raghunathan; Thomas G DeLoughery
Journal:  Obstet Gynecol Surv       Date:  2020-03       Impact factor: 3.015

Review 9.  Evaluation of unmet clinical needs in prophylaxis and treatment of venous thromboembolism in at-risk patient groups: pregnancy, elderly and obese patients.

Authors:  Benjamin Brenner; Roopen Arya; Jan Beyer-Westendorf; James Douketis; Russell Hull; Ismail Elalamy; Davide Imberti; Zhenguo Zhai
Journal:  Thromb J       Date:  2019-12-27
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.